|Development of medicine for treating malaria||Eisai entered into a joint research agreement with the University of Kentucky and Medicines for Malaria Venture to develop a new antimalarial medicine. This partnership aims to develop a new medicine that will be rapidly effective, cure in a single dose and provide lasting protection against reinfection. A Phase I clinical study is on-going.|
|Development of medicine for treating malaria||Takeda is working with Medicines for Malaria Venture (MMV) on a screening project to obtain hit compounds for antimalarial drugs.
Takeda is collaborating with Medicines for Malaria Venture (MMV) and the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne to carry out two antimalarial lead compound search projects.
Takeda is collaborating with Medicines for Malaria Venture (MMV) to carry out one antimalarial lead compound search project.
|Development of medicine for treating malaria||Eisai and the Broad Institute work together and identified BRD5018, a compound with the potential to be used in clinical trials. The goal of this research is to develop an oral medicine that will rapidly cure malaria, and by interrupting the transmission of malaria parasites, will prevent malaria reinfection.|
|Development of medicine for treating malaria||Eisai has identified GWT1 as a novel drug target of malaria parasites, and also identified E1511, a compound that inhibit the function of GWT1. Preclinical research in collaboration with Medicines for Malaria Venture (MMV) is in progress,|
|Screening programs for containing infections in developing countries (GHIT Fund programs)||Eisai is participating in the GHIT Fund-sponsored program to screen for candidate compounds for treating malaria, leishmaniasis and Chagas disease.|
|Screening programs for containing infections in developing countries (GHIT Fund programs)||Daiichi Sankyo RD Novare is engaged in the GHIT fund-sponsored screening program for the discovery of malaria drug candidates using a natural product library.|
|Screening programs for containing infections in developing countries (GHIT Fund programs)||Mitsubishi Tanabe Pharma is part of a GHIT Fund-sponsored program for searching out candidate drugs for treating tuberculosis and malaria, and provides its original library of compounds in the program. Regarding malaria, we aim to create PC candidates through structural optimization research based on promising compounds found through screening.|
|Screening programs for containing infections in developing countries (GHIT Fund programs)||Astellas engages in GHIT Fund-sponsored screening programs to find drug candidates for the treatment of tuberculosis and malaria. Astellas provides its original library of compounds in the programs. Astellas also engages in a GHIT Fund-sponsored Hit-to-Lead program to find lead compounds for the treatment of NTDs (leishmaniasis and Chagas disease). Astellas provides its original library of compounds in the program.|
|Development of medicine for treating malaria||Sumitomo Dainippon Pharma is engaged in the preclinical development for a new malaria transmission-blocking vaccine (TBV), which incorporates an optimized immunogen, Pfs230D1+ that was discovered by Ehime University and PATH, formulated with Sumitomo Dainippon Pharma's novel TLR7 adjuvant (DSP-0546E).
This project, which Sumitomo Dainippon Pharma and Ehime University are jointly conducting with PATH, has been awarded a grant from the GHIT Fund.
When launched, the TBV could be a transformational tool to aid the elimination of malaria.